Interim FDA-Mandated Postmarket Study Finds Essure Has Significantly Higher Rates Of Adverse Events
As expected based on retrospective data, new results from an ongoing postmarket study has found Bayer’s Essure birth control device has significantly higher rates of major adverse events compared to women who undergo tubal ligation.